Show simple item record

dc.contributor.advisorRobert S. Langer and Michael J. Cima.en_US
dc.contributor.authorMasi, Byron C. (Byron Colley)en_US
dc.contributor.otherMassachusetts Institute of Technology. Dept. of Chemical Engineering.en_US
dc.date.accessioned2013-01-23T20:22:34Z
dc.date.available2013-01-23T20:22:34Z
dc.date.copyright2012en_US
dc.date.issued2012en_US
dc.identifier.urihttp://hdl.handle.net/1721.1/76564
dc.descriptionThesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering, 2012.en_US
dc.descriptionCataloged from PDF version of thesis.en_US
dc.descriptionIncludes bibliographical references (p. 108-112).en_US
dc.description.abstractGlioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor. Treatment of GBM is a daunting task with median survival just at 21 months. Methods of localized delivery have achieved moderate success in treating GBM. Depot devices have been limited due to the relatively narrow drug distribution profile they achieve. Convection enhanced delivery has demonstrated that broad distribution is key, but is limited due to uncertain spatial distribution and serious side effects. Miniaturized depot devices, implanted into the tissue surrounding the tumor resection site, could achieve a broad aggregate distribution profile. The capabilities of localized delivery can be enhanced by utilizing microelectromechanical systems (MEMS) technology to deliver drugs with precise temporal control over release kinetics. An intracranial MEMS based device was developed to deliver the clinically utilized chemotherapeutic temozolomide (TMZ) in a 9L rodent glioma model. An activation mechanism based on thermally induced membrane failure was developed and incorporated. The kinetics of TMZ release were validated and quantified in vitro. The safety of implanting the device intracranially was confirmed. The impact of TMZ release kinetics on survival was investigated by comparing the effects of drug release rates and timing. TMZ delivered from the device prolonged animal survival. The results from the in vivo efficacy studies indicate that early, rapid delivery of TMZ from the device results in the most prolonged animal survival. This miniaturized MEMS device holds tremendous potential for the treatment of GBM and related diseases. Circuit diseases are neurological disorders that arise from the dynamic miscommunication within a neural circuit. Anxiety, mood disorders, and the chronic effects of traumatic brain injury (e.g. Parkinsonism) are prevalent, and are circuit diseases. Circuit diseases could be clinically addressed by a technology capable of electrical, and chemical neuro-modulation. A catheter based device capable of simultaneous infusion of multiple fluids and electrical stimulation was designed and fabricated. Preliminary in vitro infusion studies indicate that the reliable and reproducible infusion of multiple fluids is possible. Future work will focus on improving the biocompatibility of the device and studying the performance of the device in non-human primate models of neurological disorders.en_US
dc.description.statementofresponsibilityby Byron C. Masi.en_US
dc.format.extent112 p.en_US
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsM.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582en_US
dc.subjectChemical Engineering.en_US
dc.titleDeveloping & applying a miniaturized active microchip deviceen_US
dc.title.alternativeDeveloping and applying a miniaturized active microchip deviceen_US
dc.typeThesisen_US
dc.description.degreePh.D.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Chemical Engineering
dc.identifier.oclc822487783en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record